Open-label study of valacyclovir 1.5g twice daily for the treatment of uncomplicated herpes zoster in immunocompetent patients 18 years of age or older

Journal of Cutaneous Medicine and Surgery

Volumn 11, Issue 3, 2007, Pages 89-98

  Madkan, Vandana K ^a,b,c,d   Arora, Anita ^a,b,c,d   Babb Tarbox, Michelle ^a,b,c,d   Aboutlabeti, Sina ^a,b,c,d   Tyring, Stephen ^a,b,c,d  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b CENTER FOR CLINICAL STUDIES   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VALACICLOVIR; ACICLOVIR; ANTIVIRUS AGENT; DRUG DERIVATIVE; PRODRUG; VALINE;

ABNORMAL SENSATION; ADULT; ANOREXIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; ETHNICITY; FEMALE; HERPES ZOSTER; HUMAN; IMMUNOCOMPROMISED PATIENT; INFECTION; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MYASTHENIA; NAUSEA; PAIN; PATIENT COMPLIANCE; PATIENT SELECTION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SPINAL GANGLION; THOUGHT DISORDER; TREATMENT DURATION; UNCOMPLICATED HERPES ZOSTER; VARICELLA ZOSTER VIRUS; VIRUS REACTIVATION; VIRUS RESISTANCE; VOMITING; WOUND HEALING; AGE; AGED; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG EFFECT; FOLLOW UP; IMMUNOCOMPETENCE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; POSTHERPETIC NEURALGIA; SAFETY; SENSORY DYSFUNCTION; TREATMENT OUTCOME;

ACYCLOVIR; ADMINISTRATION, ORAL; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HERPES ZOSTER; HUMANS; IMMUNOCOMPETENCE; MALE; MIDDLE AGED; NEURALGIA, POSTHERPETIC; PLACEBOS; PRODRUGS; QUALITY OF LIFE; SAFETY; SENSATION DISORDERS; TREATMENT OUTCOME; VALINE; WOUND HEALING;

EID: 34548654219     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2007.00016     Document Type: Article

References (29)

1. Hope-Simpson RE. The nature of herpes zoster; a long term study and a new hypothesis. Proc R Soc Med 1965;58:9-20.
2. Wentworth BB, Alexander ER. Seroepidemiology of infections due to members of the herpes virus group. Am J Epidemiol 1971;94: 496-507.
3. Ragozzino MW, Melton LJ, Kurland LT, et al. Population-based study of herpes zoster and its sequelae. Medicine 1982;61:310-6.
4. De Moragas JM, Kierland RR. The outcome of patients with herpes zoster. Am Med Assoc Arch Dermatol 1957;75:193-6.
5. Miller AE. Selective decline in cellular immune response to varicella zoster in elderly. Neurology 1980;30:582-7.
6. Burke BL, Steele RW, Beard OW, et al. Immune response to varicella zoster in the aged. Arch Intern Med 1982;142:291-3.
7. Gnann JW Jr, Whitley RJ. Herpes zoster. N Engl J Med 2002;347: 340-6.
8. Schon F, Mayer ML, Kelly JS. Pathogenesis of post-herpetic neuralgia. Lancet 1987;2:366-8.
9. Lee AT. Clinics in neurology. Herpes zoster and post-herpetic neuralgia. Hong Kong Med Assoc 1988;40:295-8.
10. Burgoon CF, Burgoon JS, Baldridge GD. The natural history of herpes zoster. J Am Med Assoc 1957;164:265-9.
11. Hope-Simpson RE. Herpes zoster in general practice. Postherpetic neuralgia. J R Coll Gen Pract 1975;25:571-5.
12. Wood MJ. Herpes zoster in immunocompetent patients. Res Clin Forums 1986;8:61-8.
13. Cobo LM, Foulks GN, Liesegang T, et al. Observations on the natural history of herpes zoster ophthalmicus. Curr Eye Res 1987;6: 195-9.
14. Jackson JL, Gibbons R, Meyer G, Inouye L. The effect of treating herpes zoster with oral acyclovir in preventing postherpetic neuralgia. Arch Intern Med 1997;157:909-12.
15. Wood MJ, Ogan PH, McKendrick MW, et al. Efficacy of oral acyclovir treatment of acute herpes zoster. Am J Med 1988;85 Suppl 2A:79-83.
16. Morton P, Thomson AN. Oral acyclovir in the treatment of herpes zoster in general practice. N Z Med J 1989;102:93-5.
17. Huff JC, Bean B, Balfour HH, et al. Therapy of herpes zoster with oral acyclovir. Am J Med 1988;85 Suppl 2A:84-9.
18. Harding SP, Porter SM. Oral acyclovir in herpes zoster ophthalmicus. Curr Eye Res 1991;10:177-82.
19. Crooks RJ, Fiddian AP, Jones DA. Zoster-associated chronic pain: an overview of clinical trials with acyclovir. Scand J Infect Dis 1991; 78:62-8.
20. Huff JC, Drucker JL, Clemmer A, et al. Effect of oral acyclovir on pain resolution in herpes zoster: a reanalysis. J Med Virol 1993; Suppl 1:93-6.
21. Beutner KR, Friedman DJ, Forszpaniak C, et al. Valacylcovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995; 39:1546-53.
22. Richter A, Anton SE, Koch P, Dennett SL. The impact of reducing dose frequency on health outcomes. Clin Ther 2003;25:2307-35, discussion 2306.
23. Beutner KR. Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy. Antiviral Res 1995;28:281-90.
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;52:457-81.
25. Tyring S, Beutner KR, Tucker BA, et al. Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med 2000;9:863-9.
26. Tyring S, Barbarash RA, James NE, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. Ann Intern Med 1995;123:89-96.
27. Cobo LM, Foulks GN, Liesegang T, et al. Oral acyclovir in the treatment of acute herpes zoster ophthalmicus. Ophthalmology 1986;93:763-70.
28. Johnson RW, Dworkin RH. Treatment of herpes zoster and postherpetic neuralgia. BMJ 2003;326:748-50.
29. Sclar DA, Tartaglione TA, Fine MJ. Overview of issues related to medical compliance with implications for the outpatient management of infectious diseases. Infect Agents Dis 1994;3:266-73.